[HTML][HTML] Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease: A systematic review
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing,
affecting around 46 million people worldwide but few treatments are currently available. The …
affecting around 46 million people worldwide but few treatments are currently available. The …
Insights into Alzheimer's disease from single-cell genomic approaches
Alzheimer's disease (AD) is an age-related disease pathologically defined by the deposition
of amyloid plaques and neurofibrillary tangles in the brain parenchyma. Single-cell profiling …
of amyloid plaques and neurofibrillary tangles in the brain parenchyma. Single-cell profiling …
Lipid-accumulated reactive astrocytes promote disease progression in epilepsy
ZP Chen, S Wang, X Zhao, W Fang, Z Wang, H Ye… - Nature …, 2023 - nature.com
Reactive astrocytes play an important role in neurological diseases, but their molecular and
functional phenotypes in epilepsy are unclear. Here, we show that in patients with temporal …
functional phenotypes in epilepsy are unclear. Here, we show that in patients with temporal …
Alzheimer's and Parkinson's disease therapies in the clinic
P Chopade, N Chopade, Z Zhao… - Bioengineering & …, 2023 - Wiley Online Library
Alzheimer's disease (AD) and Parkinson's disease (PD) are the most prevalent
neurodegenerative diseases, affecting millions and costing billions each year in the United …
neurodegenerative diseases, affecting millions and costing billions each year in the United …
Biomedical knowledge graph learning for drug repurposing by extending guilt-by-association to multiple layers
Computational drug repurposing aims to identify new indications for existing drugs by
utilizing high-throughput data, often in the form of biomedical knowledge graphs. However …
utilizing high-throughput data, often in the form of biomedical knowledge graphs. However …
Targeting synapse function and loss for treatment of neurodegenerative diseases
Synapse dysfunction and loss are hallmarks of neurodegenerative diseases that correlate
with cognitive decline. However, the mechanisms and therapeutic strategies to prevent or …
with cognitive decline. However, the mechanisms and therapeutic strategies to prevent or …
Targeting epigenetics: A novel promise for Alzheimer's disease treatment
So far, the search for a cure for Alzheimer Disease (AD) has been unsuccessful. The only
approved drugs attenuate some symptoms, but do not halt the progress of this disease …
approved drugs attenuate some symptoms, but do not halt the progress of this disease …
Functional excitatory to inhibitory synaptic imbalance and loss of cognitive performance in people with Alzheimer's disease neuropathologic change
Individuals at distinct stages of Alzheimer's disease (AD) show abnormal
electroencephalographic activity, which has been linked to network hyperexcitability and …
electroencephalographic activity, which has been linked to network hyperexcitability and …
Subclinical epileptiform activity in dementia with Lewy bodies
Background Patients with dementia with Lewy bodies (DLB) have a higher probability of
seizures than in normal aging and in other types of neurodegenerative disorders …
seizures than in normal aging and in other types of neurodegenerative disorders …
Neuronal synchrony abnormalities associated with subclinical epileptiform activity in early-onset Alzheimer's disease
Since the first demonstrations of network hyperexcitability in scientific models of Alzheimer's
disease, a growing body of clinical studies have identified subclinical epileptiform activity …
disease, a growing body of clinical studies have identified subclinical epileptiform activity …